调强放疗加同步化疗对治疗后淋巴结转移的宫颈癌患者进行治疗的临床实验观察  

Clinical observation on the treatment of cervical cancer patients with lymph node metastasis treated by intensity modulated radiotherapy plus concurrent chemotherapy

作　　者：韩晓栋[1] 任俊丽[1] 李小武[1] 杨迁妮[1] 

机构地区：[1]山西省肿瘤医院,山西太原030013

出　　处：《临床医药实践》2016年第10期730-734,共5页Proceeding of Clinical Medicine

摘　　要：目的:对治疗后出现淋巴结转移的宫颈癌患者采用调强放射治疗(IMRT)加同步化疗,或者单纯IMRT,观察两种治疗方法的临床疗效及不良反应。方法:选取100例经治疗后淋巴结转移的宫颈癌患者,其中52例采用同步放化疗,6MV-X线IMRT,同步行多西他赛加顺铂全身化疗;另48例患者给予6MV-X线IMRT。结果:放化疗组中44例患者达到临床有效缓解,第1,2,3年生存率分别为84.62%,73.08%和46.15%;单放疗组中39例患者达到临床有效缓解,第1,2,3年生存率分别为70.83%,52.08%和27.08%。放化疗组骨髓抑制、胃肠道反应较单放疗组重,差异有统计学意义。结论:治疗后转移的宫颈癌患者进行调强放疗加同步化疗,近期内具有较高的有效率,但是应积极防治不良反应。Objective：For cervical cancer patients with lymph node metastasis after treatment, the clinical efficacy and side effects of the two treatment methods were observed by using the intensity modulated radiation therapy（IMRT） plus concurrent chemotherapy and or IMRT alone. Method：Select 100 cases after treatment of lymph node metastasis of cervical cancer patients ,52 eases with concurrent chemoradiation ,6MV X - ray IMRT, synchronization, docetaxel and eisplatin chemotherapy, the other 48 cases patients given 6MV X - ray IMRT. Results ： Concurrent ehemoradiotherapy group ：44 cases of patients reached clinical remission, 1,2,and 3 years survival rate was ：84.61% and 73.08% ,46.15% ;radiotherapy group ：39 patients reached clinical remission, 1,2, and 3 years survival rate was ：70.83 % ,52.08% ,27.08% ;concurrent radiotherapy and chemotherapy group compared with radiotherapy alone group, bone marrow suppression, gastrointestinal reactions heavier, the difference is significant. Conclution：Chemotherapy with radiotherapy plus concurrent chemotherapy for patients with metastatic cervical cancer after treatment has a high efficiency in the near future, but it should be actively prevention and treatment of adverse drug reactions.

关 键 词：宫颈癌 调强放疗 化疗 

分 类 号：R737.33[医药卫生—肿瘤]